See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $293B | 4.5x | 9.8x | |
| $192B | 3.1x | 7.7x | |
| $122B | 2.3x | 7.7x | |
| $118B | 2.7x | 8.0x | |
| $66.6B | 4.1x | 12.3x | |
| $59.9B | 7.0x | 22.5x | |
| $12.6B | 6.6x | -3.9x | |
| $10.8B | 3.5x | -8.7x | |
| $8.1B | 3.9x | -42.5x | |
| $7.7B | 7.9x | 25.6x | |
| $7.6B | 26.0x | 612.3x | |
| $5.7B | 51.6x | n/a | |
| $4.5B | n/a | -5.3x | |
| $4.2B | 9.8x | 29.9x | |
| $3.5B | 5.2x | 13.9x | |
| $3.4B | n/a | n/a | |
| $2.6B | n/a | n/a | |
| $2.6B | 7.2x | 24.9x | |
| $2.5B | 6.1x | 22.8x | |
| $2.3B | n/a | n/a | |
| $2.2B | 5.0x | -79.5x | |
| $2.2B | 283.3x | -10.5x | |
| $2.0B | 2.1x | 5.9x | |
| $2.0B | 8.0x | -5.4x | |
| $1.7B | 6.7x | 288.2x | |
| $1.5B | n/a | n/a | |
| $1.4B | 4.2x | 57.6x | |
| $1.4B | n/a | n/a | |
| $1.3B | 489.0x | -8.5x | |
| $1.3B | 7.0x | 18.9x | |
| $1.3B | n/a | n/a | |
| $1.2B | n/a | n/a | |
| $1.2B | n/a | n/a | |
| $1.1B | 431.8x | -4.3x | |
| $1.1B | 36.0x | -29.9x | |
| $1.1B | 12.8x | -32.3x | |
| $1.0B | 5.0x | -38.1x | |
| $950M | 4.8x | -18.6x | |
| $905M | 5.7x | 12.2x | |
| $866M | n/a | n/a | |
| $837M | 17.8x | -4.2x | |
| $804M | n/a | -10.4x | |
| $790M | 0.7x | 2.1x | |
| $779M | 4.1x | n/a | |
| $775M | 9.3x | -71.4x | |
| $609M | 12.1x | -10.9x | |
| $588M | 13.7x | -4.0x | |
| $571M | n/a | n/a | |
| $564M | n/a | n/a | |
| $537M | n/a | n/a | |
| $535M | n/a | n/a | |
| $533M | n/a | n/a | |
| $528M | 94.3x | n/a | |
| $495M | n/a | n/a | |
| $465M | n/a | n/a | |
| $437M | 21.0x | -0.9x | |
| $403M | 2.2x | 9.2x | |
| $356M | n/a | n/a | |
| $341M | n/a | n/a | |
| $332M | n/a | -2.0x | |
| $321M | n/a | n/a | |
| $318M | 29.4x | -8.2x | |
| $305M | 242.4x | -1.0x | |
| $301M | n/a | n/a | |
| $276M | n/a | -10.0x | |
| $272M | n/a | -5.9x | |
| $234M | n/a | -9.1x | |
| $229M | 10196.3x | -1.3x | |
| $224M | 6.8x | n/a | |
| $210M | 175.1x | -4.4x | |
| $206M | n/a | n/a | |
| $191M | 105187.6x | -0.9x | |
| $163M | 57.3x | -8.6x | |
| $156M | 1.2x | n/a | |
| $137M | n/a | n/a | |
| $128M | n/a | n/a | |
| $127M | n/a | n/a | |
| $122M | 2.5x | -41.9x | |
| $122M | n/a | n/a | |
| $120M | n/a | n/a | |
| $120M | 16.7x | n/a | |
| $104M | n/a | n/a | |
| $104M | n/a | n/a | |
| $100M | n/a | -4.0x | |
| $91.5M | n/a | n/a | |
| $84.8M | n/a | n/a | |
| $82.1M | n/a | n/a | |
| $77.6M | n/a | -0.4x | |
| $66.4M | n/a | n/a | |
| $65.7M | 0.9x | -0.3x | |
| $65.2M | 20.6x | -1.8x | |
| $63.6M | 720.5x | n/a | |
| $62.2M | 31.6x | n/a | |
| $61.4M | 10.4x | n/a | |
| $56.6M | n/a | n/a | |
| $53.2M | n/a | n/a | |
| $47.6M | n/a | n/a | |
| $45.9M | n/a | n/a | |
| $43.8M | n/a | -1.3x | |
| $42.9M | n/a | n/a | |
| $42.4M | 1.0x | -0.2x | |
| $41.1M | n/a | n/a | |
| $36.4M | 7.3x | n/a | |
| $36.0M | 0.3x | 1.0x | |
| $35.9M | n/a | n/a | |
| $29.6M | 2.8x | n/a | |
| $24.6M | 24.6x | -0.9x | |
| $23.6M | n/a | -0.3x | |
| $21.5M | n/a | n/a | |
| $20.6M | n/a | n/a | |
| $19.3M | 290.1x | n/a | |
| $17.6M | n/a | n/a | |
| $15.1M | 2.1x | n/a | |
| $12.9M | n/a | n/a | |
| $12.6M | 4.0x | -0.9x | |
| $11.8M | 8.4x | -0.7x | |
| $10.2M | 379.1x | n/a | |
| $3.9M | 0.7x | n/a | |
| $3.8M | 1.5x | n/a | |
| $1.1M | 0.2x | -0.0x | |
| -$0.6M | -0.0x | n/a | |
| -$1.7M | n/a | 0.0x | |
| -$2.8M | n/a | n/a | |
| -$8.1M | -2.8x | n/a | |
| -$24.7M | -2.3x | 0.2x | |
| -$33.1M | n/a | n/a | |
| -$53.3M | n/a | n/a | |
| -$60.8M | n/a | n/a | |
| -$84.1M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies